Cytotoxic Tph-like cells are involved in persistent tissue damage in IgG4-related disease

Abstract

Objectives

The aim of this study was to determine pathological features of T peripheral helper (Tph)-like (PD-1⁺CXCR5⁻CD4⁺ T) cells in IgG4-related disease (IgG4-RD).

Methods

Tph-like cells in the blood and submandibular glands (SMGs) from IgG4-RD patients were analyzed by flow cytometry. Correlations between level of a Tph-like cell subset and clinical parameters of IgG4-RD were investigated. The cytotoxic capacity of Tph-like cells was also examined. Expression profiles of a molecule related to a Tph-like cell subset in IgG4-RD SMGs were assessed by immunohistochemistry.

Results

Tph-like cells from IgG4-RD patients highly expressed a fractalkine receptor, CX3CR1. Percentages of circulating CX3CR1⁺ Tph-like cells were significantly correlated with clinical parameters including IgG4-RD Responder Index, number of involved organs, and serum level of soluble IL-2 receptor. CX3CR1⁺ Tph-like cells abundantly possessed cytotoxic T lymphocyte-related molecules such as granzyme A, perforin, and G protein-coupled receptor 56. Functional assays revealed their cytotoxic potential against vascular endothelial cells and ductal epithelial cells. Immunohistochemistry showed that fractalkine was markedly expressed in vascular endothelial cells and ductal epithelial cells in IgG4-RD SMGs.

Conclusion

CX3CR1⁺ Tph-like cells are thought to contribute to persistent tissue injury in IgG4-RD and are a potential clinical marker and/or therapeutic target for inhibiting progression of IgG4-RD.

Keywords:

• CX3CR1
• cytotoxic molecules
• fractalkine
• IgG4-related disease
• Tph-like cells

Conflict of interest

None.

Additional information

Funding

This work was supported by grants-in-aid for scientific research from the Japanese Society for the Promotion of Science including #19K17910 (H.Y.), #18K09323 (R.K.), #19K18776 (K.M.), #18K08391 (K.S.), #18K09324 (K.T.), and #18H02632 (S.I.), the Takeda Science Foundation (R.K.) and the Bristol-Myers Squibb Foundation (S.I.).